WallStreetZenWallStreetZen

NASDAQ: APLS
Apellis Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for APLS

Based on 12 analysts offering 12 month price targets for Apellis Pharmaceuticals Inc.
Min Forecast
$41.00+11.47%
Avg Forecast
$67.67+83.98%
Max Forecast
$96.00+161.01%

Should I buy or sell APLS stock?

Based on 12 analysts offering ratings for Apellis Pharmaceuticals Inc.
Buy
Strong Buy
5 analysts 41.67%
Buy
3 analysts 25%
Hold
4 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their APLS stock forecasts and price targets.

APLS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-13
lockedlocked$00.00+00.00%2024-08-09
lockedlocked$00.00+00.00%2024-08-09
lockedlocked$00.00+00.00%2024-08-09
lockedlocked$00.00+00.00%2024-08-09
Needham
Top 1%
100
BuyReiterates$85.00+121.58%2024-08-09
HC Wainwright & Co.
Top 5%
96
BuyMaintains$83.00+116.37%2024-08-02
Jefferies
Top 32%
69
Strong BuyMaintains$80.00+108.55%2024-07-31
Piper Sandler
Bottom 10%
10
HoldInitiates Coverage On$46.00+19.92%2024-05-31
Wells Fargo
Top 2%
99
HoldMaintains$48.00+25.13%2024-05-23

1 of 2

Forecast return on equity

Is APLS forecast to generate an efficient return?
Company
172.67%
Industry
-664.61%
Market
50.01%
APLS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is APLS forecast to generate an efficient return on assets?
Company
50.46%
Industry
27.48%
APLS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

APLS earnings per share forecast

What is APLS's earnings per share in the next 3 years based on estimates from 11 analysts?
Avg 1 year Forecast
-$1.29
Avg 2 year Forecast
$0.16
Avg 3 year Forecast
$2.07

APLS revenue forecast

What is APLS's revenue in the next 3 years based on estimates from 9 analysts?
Avg 1 year Forecast
$793.1M+26.13%
Avg 2 year Forecast
$1.0B+60.31%
Avg 3 year Forecast
$1.3B+113.34%
APLS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

APLS revenue growth forecast

How is APLS forecast to perform vs Biotechnology companies and vs the US market?
Company
28.73%
Industry
34.55%
Market
9.39%
APLS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
APLS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

APLS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APLS$38.36$67.67+76.40%Buy
RNA$40.54$62.83+54.99%Strong Buy
AXSM$91.03$125.50+37.87%Strong Buy
MDGL$233.00$340.36+46.08%Buy
IMVT$29.05$47.00+61.79%Strong Buy

Apellis Pharmaceuticals Stock Forecast FAQ

Is Apellis Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NASDAQ: APLS) stock is to Buy APLS stock.

Out of 12 analysts, 5 (41.67%) are recommending APLS as a Strong Buy, 3 (25%) are recommending APLS as a Buy, 4 (33.33%) are recommending APLS as a Hold, 0 (0%) are recommending APLS as a Sell, and 0 (0%) are recommending APLS as a Strong Sell.

If you're new to stock investing, here's how to buy Apellis Pharmaceuticals stock.

What is APLS's earnings growth forecast for 2024-2026?

(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.61%.

Apellis Pharmaceuticals's earnings in 2024 is -$332,893,000.On average, 11 Wall Street analysts forecast APLS's earnings for 2024 to be -$157,297,743, with the lowest APLS earnings forecast at -$203,349,768, and the highest APLS earnings forecast at -$118,113,338. On average, 11 Wall Street analysts forecast APLS's earnings for 2025 to be $19,592,202, with the lowest APLS earnings forecast at -$103,501,379, and the highest APLS earnings forecast at $164,384,543.

In 2026, APLS is forecast to generate $252,360,715 in earnings, with the lowest earnings forecast at $29,223,919 and the highest earnings forecast at $628,314,252.

What is APLS's revenue growth forecast for 2024-2026?

(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 28.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.55%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.39%.

Apellis Pharmaceuticals's revenue in 2024 is $628,786,000.On average, 9 Wall Street analysts forecast APLS's revenue for 2024 to be $96,568,369,383, with the lowest APLS revenue forecast at $92,812,730,528, and the highest APLS revenue forecast at $99,014,289,613. On average, 9 Wall Street analysts forecast APLS's revenue for 2025 to be $122,744,111,614, with the lowest APLS revenue forecast at $111,326,083,037, and the highest APLS revenue forecast at $147,093,724,224.

In 2026, APLS is forecast to generate $163,344,780,125 in revenue, with the lowest revenue forecast at $138,862,320,451 and the highest revenue forecast at $213,091,074,000.

What is APLS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: APLS) forecast ROA is 50.46%, which is higher than the forecast US Biotechnology industry average of 27.48%.

What is APLS's Price Target?

According to 12 Wall Street analysts that have issued a 1 year APLS price target, the average APLS price target is $67.67, with the highest APLS stock price forecast at $96.00 and the lowest APLS stock price forecast at $41.00.

On average, Wall Street analysts predict that Apellis Pharmaceuticals's share price could reach $67.67 by Aug 13, 2025. The average Apellis Pharmaceuticals stock price prediction forecasts a potential upside of 76.4% from the current APLS share price of $38.36.

What is APLS's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: APLS) Apellis Pharmaceuticals's current Earnings Per Share (EPS) is -$2.73. On average, analysts forecast that APLS's EPS will be -$1.29 for 2024, with the lowest EPS forecast at -$1.67, and the highest EPS forecast at -$0.97. On average, analysts forecast that APLS's EPS will be $0.16 for 2025, with the lowest EPS forecast at -$0.85, and the highest EPS forecast at $1.35. In 2026, APLS's EPS is forecast to hit $2.07 (min: $0.24, max: $5.16).

What is APLS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: APLS) forecast ROE is 172.67%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.